Literature DB >> 1941059

The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.

R R Ellison1, R Mick, J Cuttner, C A Schiffer, R T Silver, E S Henderson, T Woliver, I Royston, F R Davey, A S Glicksman.   

Abstract

Cancer and Leukemia Group B undertook a randomized trial of intensification treatment in adults aged 15 to 79 years with acute lymphocytic leukemia (ALL) in complete remission (CR). Daunorubicin (DNR), prednisone, vincristine (VCR), intrathecal (IT) methotrexate (MTX), and asparaginase produced 177 CRs in 277 patients. One hundred fifty-one patients were randomly assigned to receive treatment as follows: 74 received intensive cytarabine and DNR, and 77 received cycles of mercaptopurine (6-MP) and MTX, followed by 6MP, MTX, VCR, and prednisone for 3 years in all. One hundred twelve patients received CNS prophylaxis. Intensification produced major myelosuppression but did not improve remission duration (median, 21 months). Of the 151 patients with CRs who entered the intensification phase, 29% remain in continuous CR (43 to 117 months); in 19 patients, CRs have lasted for longer than 7 years. No relapses occurred after 60 months. Median survival from the time of randomization was 30 months. Those under 30 years of age responded more frequently, with longer CR and survival. While 53% of those aged 15 to 19 years remain in continuous CR, 92% of patients over 59 years have relapsed. The presence of a myeloid antigen on the leukemic cells was adversely prognostic for CR achievement and for survival. Pretreatment WBC and platelet levels independently affected CR duration and survival. Early M1 marrow development presaged longer remissions. CNS relapse occurred in 47 of 256 patients with normal CSF before treatment, in 29 before CNS prophylaxis. CNS disease occurred after CNS prophylaxis in 18 patients: 13 of 61 who had received standard premaintenance and five of 51 who received intensification. No advantage in CR duration or survival resulted from intensive treatment with DNR and cytarabine following induction of CR.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941059     DOI: 10.1200/JCO.1991.9.11.2002

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

Review 1.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

Review 2.  Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.

Authors:  David E Gerber; Joan H Schiller
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

Review 3.  Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.

Authors:  E Späth-Schwalbe; G Heil; H Heimpel
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

Review 5.  Meningeosis leukaemica in adult acute lymphoblastic leukaemia.

Authors:  N Gökbuget; D Hoelzer
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

6.  High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)--a single-institution study.

Authors:  R Scherrer; P Bettelheim; K Geissler; U Jäger; P Knöbl; P A Kyrle; K Laczika; G Mitterbauer; E Neumann; B Schneider
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

7.  Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.

Authors:  Kelong Han; Laurent Claret; Alan Sandler; Asha Das; Jin Jin; Rene Bruno
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

8.  Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.

Authors:  Mouli Chakraborty; Chantal Sellier; Michel Ney; Villa Pascal; Nicolas Charlet-Berguerand; Ruben Artero; Beatriz Llamusi
Journal:  Dis Model Mech       Date:  2018-04-23       Impact factor: 5.758

Review 9.  Maintenance Therapy in AML.

Authors:  Patrick K Reville; Tapan M Kadia
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

10.  Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.

Authors:  Sook-Ryun Park; Jee Hyun Kim; Do Yeun Kim; Sehoon Lee; Sang-Yoon Lee; In Sil Choi; Sung-Soo Yoon; Seonyang Park; Byuoung-Gook Kim; Noe Kyoung Kim
Journal:  Korean J Intern Med       Date:  2003-03       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.